Trials / Completed
CompletedNCT02086045
Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Elixir Medical Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, performance and efficacy of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native coronary artery lesion designated the target lesion and up to one non-target lesion located in a separate epicardial vessel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System | percutaneous coronary |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-06-01
- Completion
- 2017-05-15
- First posted
- 2014-03-13
- Last updated
- 2023-09-07
Locations
13 sites across 6 countries: Belgium, Brazil, Denmark, Germany, New Zealand, Poland
Source: ClinicalTrials.gov record NCT02086045. Inclusion in this directory is not an endorsement.